Trial Profile

KOREAN POST-MARKETING SURVEILLANCE VYNDAMAX (Registered) CAPSULES FOR THE TREATMENT OF TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM)

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 20 Aug 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tafamidis meglumine (Primary)
Indications Cardiomyopathies; Transthyretin-related hereditary amyloidosis
Focus Adverse reactions
Sponsors Pfizer

Most Recent Events

05 Aug 2025 Planned number of patients changed from 100 to 110.
05 Aug 2025 Planned End Date changed from 30 Mar 2030 to 31 Dec 2026.
05 Aug 2025 Planned primary completion date changed from 30 Mar 2030 to 31 Dec 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com